Per ulteriori informazioni selezionare i riferimenti di interesse.
Management of psychosis in Parkinson's disease
CURRENT OPINION IN NEUROLOGY
Choosing the right dose of antipsychotics in schizophrenia - Lessons from neuroimaging studies
CNS DRUGS
Economic evaluations during early (phase II) drug development - A role forclinical trial simulations?
PHARMACOECONOMICS
Asymptomatic QTc prolongation associated with quetiapine fumarate overdosein a patient being treated with risperidone
HUMAN & EXPERIMENTAL TOXICOLOGY
Atypical antipsychotics in the treatment of schizophrenia - Validity of dropout rates as proxy measure of tolerability is unknown
BRITISH MEDICAL JOURNAL
D-2 and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Quetiapine - efficacy in different domains
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Quetiapine: efficacy and tolerability in schizophrenia
EUROPEAN NEUROPSYCHOPHARMACOLOGY
The health economic implications of treatment with quetiapine: an audit oflong-term treatment for patients with chronic schizophrenia
EUROPEAN PSYCHIATRY
Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis
CLINICAL NEUROPHARMACOLOGY
Clinical pharmacokinetics of quetiapine - An atypical antipsychotic
CLINICAL PHARMACOKINETICS
Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating
JOURNAL OF NEUROSCIENCE
A case of depersonalization-derealization syndrome during treatment with quetiapine
JOURNAL OF PSYCHOPHARMACOLOGY
Atypical antipsychotics and hyperglycaemia
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
Adverse effects of atypical antipsychotics
JOURNAL OF CLINICAL PSYCHIATRY
A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) study
CLINICAL THERAPEUTICS
Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine
EUROPEAN JOURNAL OF PHARMACOLOGY
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials
BIOLOGICAL PSYCHIATRY
Agranulocytosis and granulocytopenia associated with quetiapine
ACTA PSYCHIATRICA SCANDINAVICA
In vivo 5-HT2A receptor blockade by quetiapine - An R91150 single photon emission tomography study
PSYCHOPHARMACOLOGY
The long-term effect of quetiapine (Seroquel (TM)) monotherapy on weight in patients with schizophrenia
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
Long-term efficacy and safety of quetiapine in treatment-refractory schizophrenia: A case report
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
Quetiapine - A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease
CNS DRUGS
Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine
DEPRESSION AND ANXIETY
Atypical antipsychotic agents: A critical review
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Possible hypothyroidism associated with quetiapine
ANNALS OF PHARMACOTHERAPY
Hyperventilation associated with quetiapine
ANNALS OF PHARMACOTHERAPY
Novel antipsychotics in the treatment of psychosis and aggression associated with dementia: A meta-analysis of randomized controlled clinical trials
INTERNATIONAL PSYCHOGERIATRICS
Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group)
EUROPEAN PSYCHIATRY
Efficacy and safety of novel antipsychotics: A critical review
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Switching outpatients between atypical antipsychotics
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
Switching approach in the management of schizophrenia patients
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
Atypical antipsychotic effects of quetiapine fumarate in animal models
ACTA PHARMACOLOGICA SINICA
Quetiapine in schizophrenic patients: A high- and low-dose double-blind comparison
EUROPEAN JOURNAL OF PSYCHIATRY
Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders
JOURNAL OF CLINICAL PSYCHIATRY
Review of quetiapine side effects
JOURNAL OF CLINICAL PSYCHIATRY
Rationale and guidelines for the inpatient treatment of acute psychosis
JOURNAL OF CLINICAL PSYCHIATRY
Long-term use of quetiapine in elderly patients with psychotic disorders
CLINICAL THERAPEUTICS
Quetiapine - A review of its safety in the management of schizophrenia
DRUG SAFETY
Quetiapine for elderly patients with psychotic disorders
PSYCHIATRIC ANNALS
Seroquel in patients with schizophrenia
ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA
Atypical antipsychotic drugs: Part II
PERSPECTIVES IN PSYCHIATRIC CARE
Worsening of motor function in Parkinson's disease - A "typical" response to "atypical" antipsychotic medications
NEUROLOGY
Conversion from conventional to atypical neuroleptics - recommendations for inpatient and outpatient treatment
NERVENARZT
New antipsychotic medications: More than old wine and new bottles
BULLETIN OF THE MENNINGER CLINIC
Atypical antipsychotics and weight gain - a systematic review
ACTA PSYCHIATRICA SCANDINAVICA
Effects of recent and reference antipsychotic agents at human dopamine D-2and D-3 receptor signaling in Chinese hamster ovary cells
PSYCHOPHARMACOLOGY
Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats
PSYCHOPHARMACOLOGY
Atypical antipsychotics: are some more atypical than others?
PSYCHOPHARMACOLOGY
Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia
MOLECULAR PSYCHIATRY
Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia
CNS DRUGS
Drug metabolism and atypical antipsychotics
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Discriminant cognitive factors in responder and non-responder patients with schizophrenia
EUROPEAN PSYCHIATRY
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
SCHIZOPHRENIA RESEARCH
Schizoaffective disorder: role of atypical antipsychotics
SCHIZOPHRENIA RESEARCH
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns
SCHIZOPHRENIA RESEARCH
Cognitive improvement in schizophrenia with novel antipsychotic medications
SCHIZOPHRENIA RESEARCH
Neuroleptic-induced hyperprolactinemia
SCHIZOPHRENIA RESEARCH
Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
MOVEMENT DISORDERS
Acute quetiapine poisoning
JOURNAL OF EMERGENCY MEDICINE
Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Antipsychotics: Past and future - National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998
SCHIZOPHRENIA BULLETIN
The use of atypical antipsychotics in the management of schizophrenia
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Focus on quetiapine
CURRENT MEDICAL RESEARCH AND OPINION
Do phase III trials have clinical value?
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders
JOURNAL OF CLINICAL PSYCHIATRY
Effectiveness of antipsychotic therapy in a naturalistic setting: A comparison between risperidone, perphenazine, and haloperidol
JOURNAL OF CLINICAL PSYCHIATRY
Treatment of agitation in dementia
JOURNAL OF CLINICAL PSYCHIATRY
Antipsychotics from theory to practice: Integrating clinical and basic data
JOURNAL OF CLINICAL PSYCHIATRY
Management of psychotic aspects of Parkinson's disease
JOURNAL OF CLINICAL PSYCHIATRY
First-episode schizophrenia: The importance of early intervention and subjective tolerability
JOURNAL OF CLINICAL PSYCHIATRY
The continuing problem of extrapyramidal symptoms: Strategies for avoidance and effective treatment
JOURNAL OF CLINICAL PSYCHIATRY
The older patient: The ongoing challenge of efficacy and tolerability
JOURNAL OF CLINICAL PSYCHIATRY
Agonist-stimulated GTP gamma[S-35] binding to 5-HT1A receptors in human post-mortem brain
EUROPEAN JOURNAL OF PHARMACOLOGY
N-[C-11]METHYLSPIPERONE PET, IN CONTRAST TO [C-11] RACLOPRIDE, FAILS TO DETECT D-2 RECEPTOR OCCUPANCY BY AN ATYPICAL NEUROLEPTIC
PSYCHIATRY RESEARCH-NEUROIMAGING
QUETIAPINE - RESULTS OF 4 PHASE-II AND PHASE-III CLINICAL-TRIALS
European psychiatry
MEDICAL-CLAIMS DATABASES IN THE DESIGN OF A HEALTH-OUTCOMES COMPARISON OF QUETIAPINE (SEROQUEL) AND USUAL-CARE ANTIPSYCHOTIC MEDICATION
Schizophrenia research
QUETIAPINE, AN ATYPICAL ANTIPSYCHOTIC
Pharmacotherapy
NOVEL ANTIPSYCHOTICS, EXTRAPYRAMIDAL SIDE-EFFECTS AND TARDIVE-DYSKINESIA
International clinical psychopharmacology
CLINICAL DEVELOPMENT OF ATYPICAL ANTIPSYCHOTICS - RESEARCH DESIGN ANDEVALUATION
The Journal of clinical psychiatry
A COMPARISON OF BD AND TID DOSE REGIMENS OF QUETIAPINE (SEROQUEL) IN THE TREATMENT OF SCHIZOPHRENIA
Psychopharmacology
TIME-COURSE OF CENTRAL NERVOUS DOPAMINE-D-2 AND 5-HT2 RECEPTOR BLOCKADE AND PLASMA DRUG CONCENTRATIONS AFTER DISCONTINUATION OF QUETIAPINE (SEROQUEL(R)) IN PATIENTS WITH SCHIZOPHRENIA
Psychopharmacology
MULTIPLE FIXED DOSES OF SEROQUEL (QUETIAPINE) IN PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA - A COMPARISON WITH HALOPERIDOL AND PLACEBO
Biological psychiatry
A COMPARISON OF QUETIAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIA
Acta psychiatrica Scandinavica
IBZM SPECT IMAGING OF STRIATAL DOPAMINE-2 RECEPTORS IN PSYCHOTIC-PATIENTS TREATED WITH THE NOVEL ANTIPSYCHOTIC SUBSTANCE QUETIAPINE IN COMPARISON TO CLOZAPINE AND HALOPERIDOL
Psychopharmacology
PREVIOUS TREATMENT AS A CONFOUNDING VARIABLE IN STUDIES WITH NOVEL ANTIPSYCHOTICS - 2 CASES OF HIGH DOPAMINE-2 RECEPTOR OCCUPANCY WITH QUETIAPINE
Psychopharmacology